• Explore /
  • Poster
  • / A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.

A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.

Abstract Poster

Authors

Manisha Palta

Manisha Palta

Duke University Medical Center, Durham, NC

Manisha Palta , Brian G. Czito , Eileen Duffy , Mary Malicki , Donna Niedzwiecki , James L. Abbruzzese , Hope Elizabeth Uronis , Gerard C. Blobe , Dan G. Blazer III, Christopher Willett

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT02318095

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4121)

DOI

10.1200/JCO.2018.36.15_suppl.4121

Abstract #

4121

Poster Bd #

310

Abstract Disclosures

Similar Posters

First Author: Derek B. Grose

First Author: Derek B. Grose

First Author: Michael J. Pishvaian

First Author: Sarah E. Hoffe